PDCD1 and neoplasm: These results suggest that anti-BTLA blockade enhances the antitumor efficacy of anti-PD-L1 blockade in an anti-PD-L1 therapy-resistant tumor model, and dual BTLA and PD-1 blockade could increase CD8+ T cell infiltration and decreases Treg cell infiltration.